Bionest

Embryonic Stem Cell Technology and FDA

Stem cell research has elicited both excitement and controversy since its earliest days. Hematopoietic stem cell transplants have been employed for some time in the treatment of certain blood cancers. More recently, researchers have reported clinical successes in using bone marrow transplants to treat sickle cell disease as well as multiple sclerosis, where bone marrow...

Bionest

FDA Decision on Dexcom Device Changes Playing Field for Continuous Glucose Monitoring

At the end of March, the U.S. Food and Drug Administration approved a new continuous glucose monitor (CGM) system, the Dexcom G6. The new sensor is smaller than current CGM devices, about the size of a quarter. It comes already calibrated from the factory, thus freeing users from daily finger sticks. It is formatted as...

Bionest

Artificial Intelligence Making Gains in Health Care

Applications of artificial intelligence (AI) to health care took a major step forward with two noteworthy events in February in the cardiovascular space.   In the first case, the U.S. Food and Drug Administration (FDA) approved the marketing of a clinical decision support tool designed to flag signs of a stroke on computed tomography (CT)...